Kabir. Thank you,
COMPXXX for nearly all COMP sites been XXX. the initiated program, pivotal at have Looking
U.K., anticipate Sweden further For the the trial, in progress I initiated clients XXX we have U.S., and this Spain. Canada, year. Ireland,
strong degree this of expected, population. the need is geographies, unmet demand which, Patient all as in reflects in
XXX However, as our experiencing Kabir has delays trial. in said, in we are recruitment
are complex. trials these before, said we've As
and an has important in quality every has the U.S. been diagnosis, because medical TRD of This the the and I screening enrolling. to pace this formally slowed Schedule program. element drug redosing requirements the confirming we of and Beyond recordkeeping decentralized unique challenge and patient's is handling are a authorization protocols,
nearly that help of with enrollment. of sites. clinical sites to as COMP which mentioned, trial, we see are remains should encountered resources, increased see on Kabir now a the don't recruitment, will track. same which to all open challenges pace XXX, the we addition global U.S. However, The an improve specific XXX impacts and are have And we
excited COMPXXX of of of XX investigated announced study been whom tolerated weeks, an COMPXXX were We in profile for psilocybin. all data and the we other safety in the up COMPXXX efficacy, an indications. is that Phase demonstrated XX potential a II reported. participants look patients, this was, which December, PTS dose followed to administered with study of we safety no including data expected, events later well are to hours, XX in Separately, interest, and indication have which the spring. have set, adverse XX as also for The treatment-emergent announcing ] additional single was by initial forward safety PTSD we milligrams [ exploratory serious full
were mentioned, Kabir published study in depressive the investigator-led results another difficult-to-treat addition, potential In depression bipolar the investigational independent II XXXX announced type in psilocybin as disorder. first These of treatment for demonstrated data COMPXXX in an JAMA Psychiatry. in full
XX with met a participants in MADRS criteria scores baseline remission. and X. COMPASS. for investigated Aaronson XX The participants All Scott conducted met of support. at from Baltimore safety mean Pratt dose the study criteria The points XX-milligram to a treatment week of and funded by baseline lowered from It COMPXXX change with had score response, total Sheppard was primary MADRS endpoint week XX XX efficacy psilocybin of the X. was and minus at change psychological by for single in the
is we as small see the a this extremely results While trial, promising.
by dosing concern no on events TRD, hypermanic no particular participants or no the living out options. was most with suicidality resolving like the with those the headache for mixed or on with bipolar XX limited We which The or dosing, manic, depression, day XX bipolar onset based of the the with not reported of X People and symptoms adverse over study. score hours. is a in there the difficulties Importantly, state, see weeks XX MADRS within increase of did event sessions a II common of adverse have with disorder. living patients was unexpected
that early encouraging psilocybin have to those signals help to living with COMPXXX see it's may So potential depressive conditions. these
on and additional our study's As indication use results, mission Kabir studies this be bipolar good is indicated, consideration. are of with for COMPXXX, a to of based the This for under II company. interest an fit larger looks the type
me Mary-Rose overview. financial hand Mary-Rose? to the a Let call for now
